In an article published by Pharma DJ, life sciences partner Katherine Wang examines a new guideline released by the Center for Drug Evaluation (CDE), the technical review body under the China Food and Drug Administration (CFDA), which outlines the regulatory framework for biosimilars, aiming to address clinical needs for biologics in China by improving the accessibility and affordability of innovative products. The article is available here.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.